Matthew Foehr Biography and Net Worth

Director of Viking Therapeutics

Matthew W. Foehr, has been our President and Chief Operating Officer since January 2015. Prior to that time, Mr. Foehr served as our Executive Vice President and Chief Operating Officer since 2011, and has more than 20 years of experience managing global research and development programs. Prior to joining our company in 2011, he was Vice President and Head of Consumer Dermatology R&D, as well as Acting Chief Scientific Officer of Dermatology, in the Stiefel division of GlaxoSmithKline (GSK). Following GSK’s $3.6 billion acquisition of Stiefel in 2009, Mr. Foehr led the R&D integration of Stiefel into GSK. At Stiefel Laboratories, Inc., Mr. Foehr served as Senior Vice President of Global R&D Operations, Senior Vice President of Product Development & Support, and Vice President of Global Supply Chain Technical Services. Prior to Stiefel, Mr. Foehr held various executive roles at Connetics Corporation including Senior Vice President of Technical Operations and Vice President of Manufacturing. Mr. Foehr serves on the Board of Directors of Viking Therapeutics, Inc., a publicly-traded biotechnology company and served as a director of Ritter Pharmaceuticals, Inc. from February 2015 until its merger with Qualigen Therapeutics, Inc. in May 2020. Mr. Foehr is the author of multiple scientific publications and is named on numerous U.S. patents. He received his B.S. degree in biology from Santa Clara University.

What is Matthew W. Foehr's net worth?: The estimated net worth of Matthew W. Foehr is at least $149.42 million as of May 24th, 2024. Mr. Foehr owns 3,536,665 shares of Viking Therapeutics stock worth more than $149,424,096 as of December 21st. This net worth approximation does not reflect any other investments that Mr. Foehr may own. Learn More about Matthew W. Foehr's net worth.
How do I contact Matthew W. Foehr?: The corporate mailing address for Mr. Foehr and other Viking Therapeutics executives is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. Viking Therapeutics can also be reached via phone at (858) 704-4660 and via email at [email protected]. Learn More on Matthew W. Foehr's contact information.
Has Matthew W. Foehr been buying or selling shares of Viking Therapeutics?: Matthew W. Foehr has not been actively trading shares of Viking Therapeutics during the last quarter. Most recently, on Thursday, June 10th, Matthew W. Foehr bought 20,000 shares of Viking Therapeutics stock. The stock was acquired at an average cost of $5.69 per share, with a total value of $113,800.00. Following the completion of the transaction, the director now directly owns 66,250 shares of the company's stock, valued at $376,962.50. Learn More on Matthew W. Foehr's trading history.
Who are Viking Therapeutics' active insiders?: Viking Therapeutics' insider roster includes Matthew Foehr (Director), Brian Lian (CEO), Lawson Macartney (Director), Marianna Mancini (COO), Sarah Rouan (Director), Charles Rowland, Jr. (Director), J. Matthew Singleton (Director), and Greg Zante (CFO). Learn More on Viking Therapeutics' active insiders.
Are insiders buying or selling shares of Viking Therapeutics?: In the last year, insiders at the biotechnology company sold shares 19 times. They sold a total of 1,383,618 shares worth more than $81,779,033.02. The most recent insider tranaction occured on November, 8th when Director Lawson Macartney sold 2,000 shares worth more than $137,340.00. Insiders at Viking Therapeutics own 4.7% of the company. Learn More about insider trades at Viking Therapeutics.
Information on this page was last updated on 11/8/2024.

Matthew W. Foehr Insider Trading History at Viking Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2021	Buy	20,000	$5.69	$113,800.00	66,250
6/30/2020	Sell	13,000	$7.35	$95,550.00	26,250
11/15/2016	Buy	13,000	$1.21	$15,730.00	39,250
4/13/2016	Buy	20,000	$1.24	$24,800.00	26,250

Matthew W. Foehr Buying and Selling Activity at Viking Therapeutics

Viking Therapeutics Company Overview

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Today's Range

Now: $42.25

$41.97

$45.00

50 Day Range

MA: $57.58

$38.28

$78.03

2 Week Range

Now: $42.25

$17.23

$99.41

Volume

8,815,748 shs

Average Volume

4,483,956 shs

Market Capitalization

$4.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88

Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong

From Brownstone Research | Ad

Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.

Click here to watch this demo and decide for yourself.